1 Cancer Immunotherapies Market Overview
1.1 Product Overview and Scope of Cancer Immunotherapies
1.2 Cancer Immunotherapies Segment by Type
1.2.1 Global Cancer Immunotherapies Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Monoclonal Antibodies (MABs)
1.2.3 Cancer Vaccines
1.2.4 Immunomodulators
1.2.5 Adoptive Cell transfer
1.2.6 Checkpoint Inhibitors
1.3 Cancer Immunotherapies Segment by Application
1.3.1 Global Cancer Immunotherapies Sales Comparison by Application: (2022-2028)
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Melanoma
1.3.6 Colorectal Cancer
1.3.7 Non-Small Cell Lung Cancer
1.4 Global Cancer Immunotherapies Market Size Estimates and Forecasts
1.4.1 Global Cancer Immunotherapies Revenue 2017-2028
1.4.2 Global Cancer Immunotherapies Sales 2017-2028
1.4.3 Cancer Immunotherapies Market Size by Region: 2017 Versus 2021 Versus 2028
2 Cancer Immunotherapies Market Competition by Manufacturers
2.1 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2017-2022)
2.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Cancer Immunotherapies Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Cancer Immunotherapies Manufacturing Sites, Area Served, Product Type
2.5 Cancer Immunotherapies Market Competitive Situation and Trends
2.5.1 Cancer Immunotherapies Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Cancer Immunotherapies Players Market Share by Revenue
2.5.3 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Immunotherapies Retrospective Market Scenario by Region
3.1 Global Cancer Immunotherapies Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Cancer Immunotherapies Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Cancer Immunotherapies Market Facts & Figures by Country
3.3.1 North America Cancer Immunotherapies Sales by Country
3.3.2 North America Cancer Immunotherapies Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Cancer Immunotherapies Market Facts & Figures by Country
3.4.1 Europe Cancer Immunotherapies Sales by Country
3.4.2 Europe Cancer Immunotherapies Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Region
3.5.1 Asia Pacific Cancer Immunotherapies Sales by Region
3.5.2 Asia Pacific Cancer Immunotherapies Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Cancer Immunotherapies Market Facts & Figures by Country
3.6.1 Latin America Cancer Immunotherapies Sales by Country
3.6.2 Latin America Cancer Immunotherapies Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Country
3.7.1 Middle East and Africa Cancer Immunotherapies Sales by Country
3.7.2 Middle East and Africa Cancer Immunotherapies Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Cancer Immunotherapies Historic Market Analysis by Type
4.1 Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
4.2 Global Cancer Immunotherapies Revenue Market Share by Type (2017-2022)
4.3 Global Cancer Immunotherapies Price by Type (2017-2022)
5 Global Cancer Immunotherapies Historic Market Analysis by Application
5.1 Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
5.2 Global Cancer Immunotherapies Revenue Market Share by Application (2017-2022)
5.3 Global Cancer Immunotherapies Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Amgen Cancer Immunotherapies Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AstraZeneca Cancer Immunotherapies Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Roche Cancer Immunotherapies Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Corporation Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Corporation Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Bayer Cancer Immunotherapies Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Merck Cancer Immunotherapies Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 ARMO BioSciences (Eli Lilly)
6.6.1 ARMO BioSciences (Eli Lilly) Corporation Information
6.6.2 ARMO BioSciences (Eli Lilly) Description and Business Overview
6.6.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.4.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio
6.7.5 ARMO BioSciences (Eli Lilly) Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Corporation Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Novartis Cancer Immunotherapies Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Pfizer Cancer Immunotherapies Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Corporation Information
6.11.2 AbbVie Cancer Immunotherapies Description and Business Overview
6.11.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.11.4 AbbVie Cancer Immunotherapies Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Gilead Sciences
6.12.1 Gilead Sciences Corporation Information
6.12.2 Gilead Sciences Cancer Immunotherapies Description and Business Overview
6.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Gilead Sciences Cancer Immunotherapies Product Portfolio
6.12.5 Gilead Sciences Recent Developments/Updates
7 Cancer Immunotherapies Manufacturing Cost Analysis
7.1 Cancer Immunotherapies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Cancer Immunotherapies
7.4 Cancer Immunotherapies Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Cancer Immunotherapies Distributors List
8.3 Cancer Immunotherapies Customers
9 Cancer Immunotherapies Market Dynamics
9.1 Cancer Immunotherapies Industry Trends
9.2 Cancer Immunotherapies Market Drivers
9.3 Cancer Immunotherapies Market Challenges
9.4 Cancer Immunotherapies Market Restraints
10 Global Market Forecast
10.1 Cancer Immunotherapies Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Cancer Immunotherapies by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Cancer Immunotherapies by Type (2023-2028)
10.2 Cancer Immunotherapies Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Cancer Immunotherapies by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Cancer Immunotherapies by Application (2023-2028)
10.3 Cancer Immunotherapies Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Cancer Immunotherapies by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Cancer Immunotherapies by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
